BARCELONA, Spain & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan 18, 2021-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d`Hebron Institute of Oncology (VHIO), one of Europe`s leading cancer research organizations, have agreed to enter into a partnership to establish in-house liquid biopsy testing services, using Guardant Health`s industry-leading proprietary digital sequencing platform, at VHIO`s facility in Barcelona, Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005057/en/ The service is expected to become operational in 2021 and will be available for clinical research and...
|
